Search results
Gilead Gives Up Big Gains As Covid Drug Drives Its Beat — Again
Investor's Business Daily· 1 month agoGilead stock pared its gains Friday after Gilead Sciences beat first-quarter sales forecasts on the...
Gilead Sciences (GILD) Q4 2023 Earnings Call Transcript
Motley Fool via Yahoo Finance· 4 months agoImage source: The Motley Fool. Gilead Sciences (NASDAQ: GILD) Q4 2023 Earnings Call Feb 06, 2024,...
See Why Gilead's Cancer Business Is Driving The Stock To A Fever Pitch
Investor's Business Daily· 2 years agoGilead Sciences' first-in-class cancer drug and GILD stock are finally hitting their stride. The...
Gilead Sciences: The Bull Case Is More Powerful Than You Think
GuruFocus.com via Yahoo Finance· 6 months agoGilead Sciences Inc. (NASDAQ:GILD) is an American pharmaceutical company specializing in developing...
Gilead Snags Another Cancer Win On The Heels Of Its Best Growth In 7 Years
Investor's Business Daily· 1 year agoGilead Sciences followed up a strong quarterly report with a third Food and Drug Administration...
Gilead Breaks Out In Bullish Volume As Its Cancer Drug Sales Nearly Double
Investor's Business Daily· 2 years agoGilead Sciences crushed third-quarter expectations as sales of its cancer drugs nearly doubled,...
Gilead profit tops expectations despite lower COVID drug sales, outlook raised
Reuters via Yahoo Finance· 2 years agoGilead Sciences Inc on Thursday posted a higher-than-expected third-quarter profit on the back of...
Why Gilead Sciences Stock Dropped Today
Motley Fool via Yahoo Finance· 4 months agoShares of Gilead Sciences (NASDAQ: GILD) are down 3.7% as of 3:30 p.m. ET Wednesday after the biopharmaceuticals giant announced mixed quarterly results...
Gilead reviewing drug acquired in $5B buyout after latest setback
BioPharma Dive via Yahoo Finance· 3 months agoGilead Sciences is evaluating the future of a cancer drug acquired in a multibillion-dollar deal...
Gilead Reports 'Mildly Disappointing' Quarterly Results With An Unexpected High Point
Investor's Business Daily· 4 months agoGilead Sciences' had a "mildly disappointing" fourth quarter that featured two high-profile misses...